146 related articles for article (PubMed ID: 15543009)
1. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease.
Stoneham S; Ashley S; Pinkerton CR; Wallace WH; Shankar AG;
J Pediatr Hematol Oncol; 2004 Nov; 26(11):740-5. PubMed ID: 15543009
[TBL] [Abstract][Full Text] [Related]
2. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group.
Kesik V; Ataş E; Karakükcü M; Aksoylar S; Erbey F; Taçyıldız N; Küpesiz A; Öniz H; Ünal E; Kansoy S; Öztürk G; Elli M; Kaya Z; Ünal E; Hazar V; Yılmaz Bengoa Ş; Karasu G; Atay D; Dağdemir A; Ören H; Koçak Ü; Yeşilipek MA
Turk J Haematol; 2016 Dec; 33(4):265-272. PubMed ID: 27094103
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
5. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
9. Outcome predictors of autologous hematopoietic stem cell transplantation in children with relapsed and refractory Hodgkin lymphoma: Single-center experience in a lower-middle-income country.
Abdalla A; Hammad M; Hafez H; Zaghloul MS; Taha H; El-Hennawy G; El-Wakeel M; Khaled M; Mohamed Y; El-Haddad A
Pediatr Transplant; 2019 Sep; 23(6):e13531. PubMed ID: 31271483
[TBL] [Abstract][Full Text] [Related]
10. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
12. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
[TBL] [Abstract][Full Text] [Related]
13. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F
Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
[TBL] [Abstract][Full Text] [Related]
14. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
Tey S; Butler J; Durrant S; Hill G; Morton J; Kennedy G
Bone Marrow Transplant; 2005 Sep; 36(6):553-4; author reply 554. PubMed ID: 16044146
[No Abstract] [Full Text] [Related]
15. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen.
Gutierrez-Delgado F; Holmberg L; Hooper H; Petersdorf S; Press O; Maziarz R; Maloney D; Chauncey T; Appelbaum F; Bensinger W
Bone Marrow Transplant; 2003 Aug; 32(3):279-85. PubMed ID: 12858199
[TBL] [Abstract][Full Text] [Related]
17. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
18. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
19. Stem cell transplantation in Hodgkin lymphoma.
Reddy NM; Perales MA
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1097-112. PubMed ID: 25459181
[TBL] [Abstract][Full Text] [Related]
20. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]